Drew Y, Kim JW, Penson RT, O'Malley DM, et al. Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naive Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clin Cancer Res 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-2249.
PMID: 37939124